Ocular Toxicity Associated With Antibody–Drug Conjugates in Gynecologic Cancers: An HCP Resource

Download this resource with key information on monitoring, mitigating, and recognizing ocular adverse events associated with antibody–drug conjugates used to treat gynecologic cancers.
Format: Adobe Acrobat (.pdf)
File Size: 230 KB
Released: July 27, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genmab
Seagen

Related Content

Final OS data for PAOLA-1 phase III trial of maintenance olaparib plus bevacizumab vs placebo plus bevacizumab in newly diagnosed ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 27, 2022

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: September 26, 2022

7-year follow-up from phase III SOLO-1 trial of maintenance olaparib vs placebo in newly diagnosed advanced ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 15, 2022

Interactive online tool with expert management recommendations for selecting therapy for women with advanced endometrial cancer, from Clinical Care Options (CCO)

Maria Bell, MD, MPH, MBA Hye Sook Chon, MD Linda R. Duska, MD, MPH Ritu Salani, MD, MBA Shannon N. Westin, MD, MPH Released: September 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings